Table 1

Baseline data for patients with polymyositis and dermatomyositis and healthy controls.

Patients*

n = 23

Median (range)

Healthy controls*

n = 12

Median (range)

Exercise

group*¤

n = 9

Median (range)

Control group*¤

n = 7

Median (range)


Sex

(female/male), n

17/6

9/3

8/1

6/1

Diagnosis

(PM/DM), n

11/12

NA

4/5

3/4

Age, years

58 (37 to 77)

51 (31 to 71)

60 (48 to 72)

58 (42 to 77)

Duration since

diagnosis, years

7 (1 to 33)

NA

8 (1 to 13)

7 (2 to 33)

DMARD treatment

(GC/MTX/AZA/RITUX/MMF/CsA), n

13/9/5/2/1/1

NA

5/3/3/0/1/0

5/2/2/1/0/1

Daily GC dose, mg

5 (1 to 10)

NA

5 (1 to 8)

2 (2 to 5)

MMT-8, 0 to 80

75 (42 to 80)

NA

76 (42 to 79)

73 (57 to 77)

HAQ, 0.0 to 3.0

0.5 (0.0 to 1.8)1

NA

0.5 (0.0 to 1.4)1

0.5 (0.4 to 1.8)

CPK, μcat/l

2 (1 to 62)3

NA

2 (1 to 62)1

2 (1 to 4)1

Physician global

disease activity

VAS, 0 to 100

4 (8 to 16)2

NA

4 (0 to 14)1

2 (0 to 10)1

Patient global

disease activity

VAS, 0 to 100

39 (0 to 88)1

NA

24 (0 to 72)1

42 (3 to 77)

MITAX, 0 to 1.0

0.1 (0.0 to 0.2)2

NA

0.1 (0.0 to 0.2)

0.1 (0.1 to 0.2)1

Muscle disease activity, VAS, 0 to 100

2 (0 to 8)2

NA

2 (0 to 8)1

2 (0 to 7)1

Physician global damage VAS, 0 to 100

18 (0 to 62)2

NA

22 (7 to 62)1

22 (10 to 49)1

Muscle damage

VAS, 0 to 100

11 (0 to 39)2

NA

10 (0 to 39)1

14 (9 to 31)1


*Data in median (range) if not stated otherwise. ¤, Patients with reliable lactate levels at baseline were randomly assigned to an exercise group or a control group. AZA, Azathioprine; CPK, creatine phosphokinase (normal values <2.5 μcat/liter in women, <3.0 μcat/liter in men); CsA, Cyclosporine A; DMARD, disease modifying anti-rheumatic drugs; GC, Glucocorticoids; HAQ, Health Assessment Questionnaire; MITAX, myositis intention to treat activity index; MMF, Mycophenolate mofetil; MMT, manual muscle test; MTX, Methotrexate; NA, not assessed; PM/DM, polymyositis/dermatomyositis; RITUX, Rituximab; VAS, visual analogue scale. 1, One missing datum; 2, Two missing data; 3, Three missing data. *, No statistical difference in any of the variables between groups; patients vs HC and EG vs CG assessed by Mann-Whitney U-test (P <0.05).

Alemo Munters et al. Arthritis Research & Therapy 2013 15:R83   doi:10.1186/ar4263

Open Data